Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

Ipsen redoubled its commitment to developing treatments for fibrodysplasia ossificans progressiva by obtaining rights to an ALK2 inhibitor from

Read the full 199 word article

User Sign In